GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE283nnn/GSE283630/primaryOK200TranscriptomicsHomo sapiensExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283630GEOGSEfalsePatients who received abatacept for graft versus host disease prophylaxis have lower peri-engraftment NETosis and less endothelial injuryAbatacept decreases risk of aGVHD in adult and pediatric patient populations, but its effect on other clinical outcomes of HSCT has not been well studied. Abatacept’s effect in reducing GVHD has been linked to T-cell dependent mechanisms, but it’s effect on neutrophils and completement activation is largely unknown. In this study we analyzed the effect of abatacept prophylaxis in clinical outcomes of HSCT and explored other potential mechanisms.2026/06/30GSE283630GSM8668227GSM8668228GSM8668225GSM8668226GSM8668223GSM866822421697283630Homo sapiens